2024
Incidence of bacterial blood stream infections in patients with acute GVHD
Wallis W, Gulbis A, Wang T, Lee C, Sharma A, Williams K, Nishihori T, Prestidge T, Gowda L, Byrne M, Krem M, MacMillan M, Kitko C, Pidala J, Spellman S, Lee S, Alousi A. Incidence of bacterial blood stream infections in patients with acute GVHD. Bone Marrow Transplantation 2024, 1-6. PMID: 39420192, DOI: 10.1038/s41409-024-02426-9.Peer-Reviewed Original ResearchBacterial bloodstream infectionsHematopoietic stem cell transplantationAcute GVHDNon-relapse mortalityGrade II-IV acute GVHDAllogeneic hematopoietic stem cell transplantationGrade III/IV acute GVHDBacterial blood stream infectionsAssociated with worse survivalStem cell transplantationBlood stream infectionsHigh-risk populationGVHD treatmentNeutrophil engraftmentBloodstream infectionsWorse survivalCell transplantationGI involvementOrgan involvementPost-transplantationPost-engraftmentRisk populationHigh riskPatientsGVHDA phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.
Al Malki M, Keyzner A, Suh H, Popat U, Gill S, Chen Y, Solh M, Gowda L, Buonomo E, Wang Y, Murray J, MacBeath G, Barton D, Chattopadhyay S, Reshef R. A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. Journal Of Clinical Oncology 2024, 42: tps2678-tps2678. DOI: 10.1200/jco.2024.42.16_suppl.tps2678.Peer-Reviewed Original ResearchHematopoietic cell transplantationMinimal residual diseaseEngineered T cell therapiesPatient hematopoietic cellsT-cell therapyMinor histocompatibility antigensHematopoietic cellsHLA-A*02:01Residual diseaseCell transplantationHematologic malignanciesPost-HCTT cellsHistocompatibility antigensTreatment armsCAR-T cell therapyAllogeneic hematopoietic cell transplantationHematopoietic cell transplant patientsPrevent disease relapseRelapse post-HCTDose-limiting toxicityDisease-free survivalEngineered T cellsHaploidentical donor transplantationSurrogate of efficacy
2023
Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience
Hamouche R, Foss F, Mirza S, Di M, Isufi I, Bar N, Gowda L, Perreault S, Roberts K, Seropian S, Sethi T. Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience. Blood 2023, 142: 2172. DOI: 10.1182/blood-2023-189414.Peer-Reviewed Original ResearchT-cell lymphomaTotal body irradiationAggressive T-cell lymphomaReduced intensity conditioning regimenHematopoietic stem cell transplantationRefractory T-cell lymphomaNodal T-cell lymphomasIntensity conditioning regimenPotential curative optionStem cell transplantationConditioning regimenAdult patientsCurative optionRetrospective reviewBody irradiationCell transplantationSingle agentPatientsRegimenPentostatinAlloSCTTransplantationLymphomaPost-transplantation cyclophosphamide is associated with increased bacterial infections
Ustun C, Chen M, Kim S, Auletta J, Batista M, Battiwalla M, Cerny J, Gowda L, Hill J, Liu H, Munshi P, Nathan S, Seftel M, Wingard J, Chemaly R, Dandoy C, Perales M, Riches M, Papanicolaou G. Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplantation 2023, 59: 76-84. PMID: 37903992, PMCID: PMC11164622, DOI: 10.1038/s41409-023-02131-z.Peer-Reviewed Original ResearchConceptsPost-transplant cyclophosphamideHematopoietic cell transplantationBacterial infectionsMost bacterial infectionsGVHD prophylaxisInfection cohortHost diseaseCalcineurin inhibitorsMyelodysplastic syndromeCell transplantationAcute leukemiaMore infectionsDay 180Greater incidencePatientsInfectionCohortProphylaxisCyclophosphamideTransplantationSyndromeGraftLeukemiaMortalityIncidenceImpact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
Ragon B, Shah M, D’Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja M, Majhail N, Banerjee R, Saad A, Hildebrandt G, Mian H, Abid M, Battiwalla M, Lekakis L, Patel S, Murthy H, Nieto Y, Strouse C, Badawy S, Al Hadidi S, Dholaria B, Aljurf M, Vesole D, Lee C, Pawarode A, Gergis U, Miller K, Holmberg L, Afrough A, Solh M, Munshi P, Nishihori T, Anderson L, Wirk B, Kaur G, Qazilbash M, Shah N, Kumar S, Usmani S. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Advances 2023, 7: 2746-2757. PMID: 36827681, PMCID: PMC10275699, DOI: 10.1182/bloodadvances.2022009138.Peer-Reviewed Original ResearchConceptsSecond hematological malignanciesSecond primary malignanciesProgression-free survivalMultiple myelomaOverall survivalMaintenance therapyDevelopment of SPMsRisk of SPMAutologous hematopoietic stem cell transplantationInferior progression-free survivalHematopoietic stem cell transplantationHigh-dose melphalanMelphalan conditioning regimenSubsequent maintenance therapyStem cell transplantationFrequent primary causeCIBMTR analysisLenalidomide maintenanceAuto-HSCTConditioning regimenMedian survivalPrimary malignancyAdult patientsCell transplantationClinical trialsAssociation of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia
Murthy S, Logan B, Bo‐Subait S, Beitinjaneh A, Devine S, Farhadfar N, Gowda L, Hashmi S, Lazarus H, Nathan S, Sharma A, Yared J, Stefanski H, Pulsipher M, Hsu J, Switzer G, Panch S, Shaw B. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. American Journal Of Hematology 2023, 98: 608-619. PMID: 36606713, PMCID: PMC10290878, DOI: 10.1002/ajh.26834.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMajor ABO mismatchABO mismatchHematopoietic cell transplantationAllo-HCTAcute lymphoblastic leukemiaABO statusAcute leukemiaCell transplantationMarrow Transplant Research databaseAllogeneic hematopoietic cell transplantationBidirectional ABO mismatchDonor-recipient ABOMinor ABO mismatchNon-relapse mortalityOlder recipient agePrimary graft failurePost-transplantation outcomesWorse overall survivalDonor selection algorithmsAcute graftChronic GVHDEligible patientsHost diseasePlatelet engraftment
2022
Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
Boyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, Bacher U, Badar T, Badawy S, Battiwalla M, Bejanyan N, Bhatt V, Brown V, Castillo P, Cerny J, Copelan E, Craddock C, Dholaria B, Perez M, Ebens C, Gale R, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Iqbal M, Jamy O, Kharfan-Dabaja M, Khera N, Lazarus H, Lin R, Modi D, Nathan S, Nishihori T, Patel S, Pawarode A, Saber W, Sharma A, Solh M, Wagner J, Wang T, Williams K, Winestone L, Wirk B, Zeidan A, Hourigan C, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf D. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. Leukemia 2022, 37: 1006-1017. PMID: 36310182, PMCID: PMC10148918, DOI: 10.1038/s41375-022-01738-3.Peer-Reviewed Original ResearchConceptsPrimary induction failureAllo-HCTRIC allo-HCTComplete remissionOverall survivalConsolidation therapyAML patientsDetectable MRDRelapse riskInduction cyclesAllogeneic hematopoietic cell transplantationConsolidation cyclesPre-transplant inductionFirst complete remissionAdult AML patientsReduced-intensity conditioningBetter overall survivalHematopoietic cell transplantationRisk of relapseAllogeneic transplant outcomesCIBMTR analysisImproved OSInduction failureTransplant outcomesCell transplantationOutcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research
Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation And Cellular Therapy 2022, 28: 187.e1-187.e10. PMID: 35081472, PMCID: PMC8977261, DOI: 10.1016/j.jtct.2022.01.017.Peer-Reviewed Original ResearchConceptsDisease-free survivalTreatment-related mortalityKarnofsky performance statusT-cell depletionVivo T-cell depletionAllogeneic hematopoietic cell transplantationInferior disease-free survivalHematopoietic cell transplantationOverall survivalT-cell prolymphocytic leukemiaT-PLLPerformance statusInternational BloodCell transplantationProlymphocytic leukemiaLong-term disease-free survivalMarrow Transplant Research databasePoor long-term survivalOutcomes of alloHCTPart of conditioningPost-transplantation relapseSuboptimal performance statusMyeloablative conditioning regimenReduced-intensity conditioningInferior overall survival
2021
Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis
Murthy S, Logan B, Bo-Subait S, Beitingjaneh A, Devine S, Farhadfar N, Gowda L, Hashmi S, Lazarus H, Nathan S, Sharma A, Yared J, Stefanski H, Pulsipher M, Hsu J, Switzer G, Panch S, Shaw B. Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis. Blood 2021, 138: 907. DOI: 10.1182/blood-2021-150635.Peer-Reviewed Original ResearchAcute myeloid leukemiaNon-relapse mortalityBidirectional ABO mismatchMajor ABO mismatchABO mismatchDisease-free survivalPrimary graft failureHematopoietic cell transplantationAllo-HCTAcute lymphoblastic leukemiaOverall survivalABO statusAcute GVHDPlatelet engraftmentGraft failureGraft manipulation techniquesChronic GVHDABO incompatibilityCell transplantationCox proportional hazards regression methodsT-cell depleted graftAllogeneic hematopoietic cell transplantationGraft manipulation strategiesMinor ABO mismatchPost-transplant outcomesCorrection to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation
Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 2021, 56: 2319-2319. PMID: 34017072, PMCID: PMC8450771, DOI: 10.1038/s41409-021-01353-3.Peer-Reviewed Original ResearchImpact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation
Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 2021, 56: 2108-2117. PMID: 33864019, PMCID: PMC8425595, DOI: 10.1038/s41409-021-01261-6.Peer-Reviewed Original ResearchConceptsMeasurable residual diseaseNon-relapse mortalityDisease-free survivalAllogeneic hematopoietic cell transplantationShorter disease-free survivalAcute myeloid leukemia patientsFirst complete remissionComplete remissionHematopoietic cell transplantationMyeloid leukemia patientsOverall survivalClinical responseCell transplantationLeukemia patientsPresence of MRDDetectable measurable residual diseaseHigher non-relapse mortalityIncomplete count recoveryTime of alloHCTTransplant-related factorsShorter overall survivalLikelihood of deathAlloHCT outcomesAdult patientsBaseline characteristicsBreaking the Age Barrier: Physicians’ Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults
Mishra A, Preussler JM, Bhatt VR, Bredeson C, Chhabra S, D'Souza A, Dahi PB, Hacker ED, Gowda L, Hashmi SK, Howard DS, Jakubowski A, Jayani R, Koll T, Lin RJ, Olin RL, Popat UR, Rodriguez C, Rosko A, Sabloff M, Sorror ML, Sung AD, Ustun C, Wood WA, Burns L, Artz A. Breaking the Age Barrier: Physicians’ Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplantation And Cellular Therapy 2021, 27: 617.e1-617.e7. PMID: 33836312, PMCID: PMC8254775, DOI: 10.1016/j.jtct.2021.03.028.Peer-Reviewed Original ResearchConceptsAllogeneic hematopoietic cell transplantationHematopoietic cell transplantationGeriatric assessmentOlder adultsPatient ageCell transplantationHCT physiciansHigh-volume teaching hospitalStandardized geriatric assessmentTransplantation-related morbidityAge 75 yearsSignificant unmet needOnline cross-sectional surveyHealth assessment toolClinical support staffCross-sectional surveyMyeloablative regimenRegimen intensityNonmyeloablative conditioningRisk stratificationTransplant physiciansTeaching hospitalAge 41Most physiciansUnmet need
2020
574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation
Schiffer M, Perreault S, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases 2020, 7: s352-s352. PMCID: PMC7776323, DOI: 10.1093/ofid/ofaa439.768.Peer-Reviewed Original ResearchCytokine release syndromeHaploidentical hematopoietic stem cell transplantationHematopoietic stem cell transplantationFebrile neutropeniaHaplo-HSCTStem cell transplantationRelease syndromeBreakthrough infectionsCell transplantationRecurrent feverEmpiric broad-spectrum antibiotic therapyRates of FNBroad-spectrum antibiotic therapyMulti-drug resistant organismsHaplo-HSCT patientsNon-infectious complicationsPost-transplant cyclophosphamideStem cell infusionBlood culture dataPositive blood culturesBroad-spectrum antibioticsYale New Haven HealthBackground FeverAntibacterial prophylaxisSecondary endpointsOutcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas
Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationMF/SSTime of transplantStem cell transplantationT-cell lymphomaMedian followCell transplantationCell lymphomaPrimary cutaneous gamma-delta T-cell lymphomaCutaneous gamma-delta T-cell lymphomaGamma-delta T-cell lymphomaMF/SS patientsLong-term complete responseCutaneous T-cell lymphomaTotal skin electron beamRefractory mycosis fungoidesClinical complete remissionDisease-free survivalComplete remissionOverall survivalPartial responseSkin involvementComplete responseMycosis fungoidesSS patientsAttenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib
Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunocompromised HostLymphoma, T-CellMaleMiddle AgedNitrilesPandemicsPneumonia, ViralPyrazolesPyrimidinesSARS-CoV-2Severity of Illness IndexTransplantation, HomologousTreatment OutcomeConceptsAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant patientsSevere acute respiratory syndrome coronavirus 2SARS coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 pneumoniaAcute respiratory syndrome coronavirus 2Stem cell transplant patientsSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Coronavirus 2 infectionCell transplant patientsCoV-2 infectionStem cell transplantationSyndrome coronavirus 2High death rateImmunocompromised stateJAK/STAT inhibitor ruxolitinibTransplant patientsCell transplantationCoronavirus 2Novel therapiesInhibitor ruxolitinibPatientsDeath rateRuxolitinibHematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D’Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 2020, 34: 3338-3347. PMID: 32313109, PMCID: PMC7572530, DOI: 10.1038/s41375-020-0830-0.Peer-Reviewed Original ResearchConceptsPrimary plasma cell leukemiaHematopoietic cell transplantationKarnofsky performance statusPlasma cell leukemiaAllo-HCTPPCL patientsCell leukemiaNovel agent eraGood partial responseOutcomes of patientsHigh relapse rateAgent eraHCT utilizationSuperior OSPartial responsePerformance statusInferior survivalMedian ageRelapse rateCell transplantationSEER dataMortality 7Multi-variate analysisPatientsSurvival 17Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes
Shallis RM, Podoltsev NA, Gowda L, Zeidan AM, Gore SD. Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes. Expert Review Of Hematology 2020, 13: 447-460. PMID: 32182435, DOI: 10.1080/17474086.2020.1744433.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAllogeneic stem cell transplantationStem cell transplantationAcute myeloid leukemiaMyelodysplastic syndromeMDS patientsRisk stratificationCell transplantationPrognostic toolLower-risk myelodysplastic syndromesHigh-risk myelodysplastic syndromeLow-risk MDS patientsSevere bone marrow failureLow-risk diseaseLow-risk patientsOnly curative optionPrognosis of patientsBone marrow failureAggressive therapyCurative optionPrognostic impactEtiologic roleDisease progressionMyeloid leukemiaAlloSCTPatientsTransplant Physicians’ Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool
Mishra A, Preussler J, Al-Mansour Z, Bachanova V, Bhatt V, Bredeson C, Chhabra S, D'Souza A, Dahi P, DeFilipp Z, Gowda L, Hacker E, Hashmi S, Howard D, Jakubowski A, Jayani R, Johnston L, Koll T, Lin R, McCurdy S, Michaelis L, Muffly L, Nathwani N, Olin R, Popat U, Rodriguez C, Rosko A, Runaas L, Sabloff M, Shore T, Shune L, Sorror M, Sung A, Ustun C, Wood W, Burns L, Artz A. Transplant Physicians’ Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool. Transplantation And Cellular Therapy 2020, 26: s45-s46. DOI: 10.1016/j.bbmt.2019.12.115.Peer-Reviewed Original ResearchHematopoietic cell transplantationKarnofsky performance scoreTransplant physiciansUpper age limitAllogeneic hematopoietic cell transplantationGeriatric assessment toolsNon-myeloablative conditioningMarrow Transplant ResearchOnline cross-sectional surveyHealth assessment toolMajority of centersClinical support staffCross-sectional surveyAssessment toolAdult physiciansMyeloablative regimenOlder ptsRegimen intensityConditioning regimensOlder patientsSupportive careInternational BloodRisk stratificationCell transplantationCurative potential
2019
Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation
Patel S, Girnius S, Dhakal B, Gowda L, Fraser R, Davila O, Shah N, Qazilbash M, Kumar S, D'Souza A, Hari P. Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation. Blood 2019, 134: 266. DOI: 10.1182/blood-2019-127049.Peer-Reviewed Original ResearchPrimary plasma cell leukemiaNon-relapse mortalityHematopoietic cell transplantationProgression-free survivalHigh-risk cytogeneticsMonths of diagnosisRelapse/progressionPPCL patientsOverall survivalMedian ageCell transplantationNovel agentsDisease statusLower non-relapse mortalityRare plasma cell neoplasmAdvisory CommitteeMultiple myeloma's (MM) outcomePost-HCT outcomesKarnofsky performance scoreSpeakers bureauSuperior overall survivalTotal body irradiationMarrow Transplant ResearchPlasma cell leukemiaPlasma cell neoplasmsPeripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.Peer-Reviewed Original ResearchAutologous stem cell transplantationAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaTime of diagnosisPeripheral blood involvementBone marrow involvementStem cell transplantationMedian progression-free survivalOverall survivalCell lymphomaBlood involvementFirst remissionMarrow involvementPrognostic factorsCell transplantationFlow cytometryPeripheral bloodWorse outcomesPositive groupNegative groupExtranodal natural killer T-cell lymphomaBone marrowFront autologous stem cell transplantationNatural killer T-cell lymphoma